Immunogenicity and protective efficacy of the norovirus P particle-M2e chimeric vaccine in chickens

Vaccine

Volumn 33, Issue 38, 2015, Pages 4901-4909

  Elaish, M ^a,b   Kang, K I ^a   Xia, M ^c   Ali, A ^a,d   Shany, S A S ^a,d   Wang, L ^c   Jiang, X ^c   Lee, C W ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d Beni Suef University   (Egypt)

Author keywords

Influenza; M2e; Norovirus P particle; Vaccine

Indexed keywords

AVIAN INFLUENZA VACCINE; MATRIX PROTEIN; MATRIX PROTEIN 2; UNCLASSIFIED DRUG; DRUG CARRIER; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; M2 PROTEIN, INFLUENZA A VIRUS; OIL; RECOMBINANT VACCINE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; AVIAN INFLUENZA; CHICKEN MODEL; CHIMERA; CONTROLLED STUDY; CROSS PROTECTION; DRUG EFFICACY; GERMFREE CHICKEN; HEMAGGLUTINATION INHIBITION; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA A VIRUS; INFLUENZA A VIRUS (H5N2); INFLUENZA A VIRUS (H6N2); INFLUENZA A VIRUS (H7N2); NONHUMAN; NOROVIRUS; NOROVIRUS P PARTICLE; PRIORITY JOURNAL; VACCINATION; VIRUS GENOME; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS SHEDDING; ANIMAL; BLOOD; CHICKEN; CLOACA; GENETICS; IMMUNOLOGY; INFLUENZA IN BIRDS; MUCOSAL DRUG ADMINISTRATION; POULTRY DISEASES; SUBCUTANEOUS DRUG ADMINISTRATION; TRACHEA; TREATMENT OUTCOME; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, MUCOSAL; ANIMALS; ANTIBODIES, VIRAL; CHICKENS; CLOACA; DRUG CARRIERS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA IN BIRDS; INFLUENZA VACCINES; INJECTIONS, SUBCUTANEOUS; NOROVIRUS; OILS; POULTRY DISEASES; TRACHEA; TREATMENT OUTCOME; VACCINES, SYNTHETIC; VIRAL MATRIX PROTEINS; VIRUS SHEDDING;

EID: 84940718597     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.07.049     Document Type: Article

References (35)

1. Palese P., Shaw M.L. Orthomyxoviridae: the viruses and their replication. Fields virology 2007, 1648-1689. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, PA. D.M. Knipe, P.M. Howley (Eds.).
2. Fouchier R.A., Munster V., Wallensten A., Bestebroer T.M., Herfst S., Smith D., et al. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J Virol 2005, 79:2814-2822.
3. Webster R.G., Bean W.J., Gorman O.T., Chambers T.M., Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol Rev 1992, 56:152-179.
4. Wu Y., Tefsen B., Shi Y., Gao G.F. Bat-derived influenza-like viruses H17N10 and H18N11. Trends Microbiol 2014, 22:183-191.
5. Molinari N.A., Ortega-Sanchez I.R., Messonnier M.L., Thompson W.W., Wortley P.M., Weintraub E., et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007, 25:5086-5096.
6. Swayne D.E., Halvorson D.A. Influenza. Diseases of poultry 2008, 153-184. Blackwell Pub, Ames, IA. Y.M. Saif, A.M. Fadly (Eds.).
7. Swayne D.E. Avian influenza control strategies. Avian influenza 2008, 287-297. Blackwell Publishing Ltd., Ames, Iowa.
8. Swayne D.E., Kapczynski D.R. Vaccines, vaccination, and immunology for avian influenza viruses in poultry. Avian influenza 2008, 407-451. Blackwell Publishing Ltd., Ames, Iowa.
9. Kapczynski D.R., Swayne D.E. Influenza vaccines for avian species. Curr Top Microbiol Immunol 2009, 333:133-152.
10. Johansson B.E., Brett I.C. Changing perspective on immunization against influenza. Vaccine 2007, 25:3062-3065.
11. Lee C.W., Suarez D.L. Avian influenza virus: prospects for prevention and control by vaccination. Anim Health Res Rev 2005, 6:1-15.
12. Swayne D.E., Beck J.R., Garcia M., Stone H.D. Influence of virus strain and antigen mass on efficacy of H5 avian influenza inactivated vaccines. Avian Pathol 1999, 28:245-255.
13. Swayne D.E., Kapczynski D. Strategies and challenges for eliciting immunity against avian influenza virus in birds. Immunol Rev 2008, 225:314-331.
14. Zhang Y., Yin Y., Bi Y., Wang S., Xu S., Wang J., et al. Molecular and antigenic characterization of H9N2 avian influenza virus isolates from chicken flocks between 1998 and 2007 in China. Vet Microbiol 2012, 156:285-293.
15. Du L., Zhou Y., Jiang S. Research and development of universal influenza vaccines. Microbes Infect 2010, 12:280-286.
16. Ebrahimi S.M., Tebianian M. Influenza A viruses: why focusing on M2e-based universal vaccines. Virus Genes 2011, 42:1-8.
17. De Filette M., Martens W., Smet A., Schotsaert M., Birkett A., Londoño-Arcila P., et al. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. Vaccine 2008, 26:6503-6507.
18. Dabaghian M., Latify A.M., Tebianian M., Nili H., Ranjbar A.R., Mirjalili A., et al. Vaccination with recombinant 4×M2e.HSP70c fusion protein as a universal vaccine candidate enhances both humoral and cell-mediated immune responses and decreases viral shedding against experimental challenge of H9N2 influenza in chickens. Vet Microbiol 2014, 174:116-126.
19. Ebrahimi S.M., Tebianian M., Toghyani H., Memarnejadian A., Attaran H.R. Cloning, expression and purification of the influenza A (H9N2) virus M2e antigen and truncated Mycobacterium tuberculosis HSP70 as a fusion protein in Pichia pastoris. Protein Expr Purif 2010, 70:7-12.
20. Song J.M., Wang B.Z., Park K.M., Van Rooijen N., Quan F.S., Kim M.C., et al. Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS ONE 2011, 6:e14538.
21. Liu W., Peng Z., Liu Z., Lu Y., Ding J., Chen Y.H. High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity. Vaccine 2004, 23:366-371.
22. Layton S.L., Kapczynski D.R., Higgins S., Higgins J., Wolfenden A.D., Liljebjelke K.A., et al. Vaccination of chickens with recombinant Salmonella expressing M2e and CD154 epitopes increases protection and decreases viral shedding after low pathogenic avian influenza challenge. Poult Sci 2009, 88:2244-2252.
23. Reese K.A., Lupfer C., Johnson R.C., Mitev G.M., Mullen V.M., Geller B.L., et al. A novel lactococcal vaccine expressing a peptide from the M2 antigen of H5N2 highly pathogenic avian influenza A virus prolongs survival of vaccinated chickens. Vet Med Int 2013, 2013:316926.
24. Tang Y., Gong Y., Wang Y., Wu P., Liu Y., Lu J., et al. Chimaeric VP2 proteins from infectious bursal disease virus containing the N-terminal M2e of H9 subtype avian influenza virus induce neutralizing antibody responses to both viruses. Avian Pathol 2013, 42:260-267.
25. Babapoor S., Neef T., Mittelholzer C., Girshick T., Garmendia A., Shang H., et al. A novel vaccine using nanoparticle platform to present immunogenic M2e against avian influenza infection. Influenza Res Treat 2011, 2011:126794.
26. Xia M., Tan M., Wei C., Zhong W., Wang L., McNeal M., et al. A candidate dual vaccine against influenza and noroviruses. Vaccine 2011, 29:7670-7677.
27. Lee C.W., Senne D.A., Suarez D.L. Generation of reassortant influenza vaccines by reverse genetics that allows utilization of a DIVA (Differentiating Infected from Vaccinated Animals) strategy for the control of avian influenza. Vaccine 2004, 22:3175-3181.
28. Ali A., Yassine H., Awe O.O., Ibrahim M., Saif Y.M., Lee C.W. Replication of swine and human influenza viruses in juvenile and layer turkey hens. Vet Microbiol 2013, 163:71-78.
29. Lee C.W., Suarez D.L. Application of real-time RT-PCR for the quantitation and competitive replication study of H5 and H7 subtype avian influenza virus. J Virol Methods 2004, 119:151-158.
30. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999, 5:1157-1163.
31. Tan M., Huang P., Xia M., Fang P.A., Zhong W., McNeal M., et al. Norovirus P particle, a novel platform for vaccine development and antibody production. J Virol 2011, 2011(85):753-764.
32. Tan M., Jiang X. Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus. Nanomedicine 2012, 7:889-897.
33. Jegerlehner A., Schmitz N., Storni T., Bachmann M.F. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004, 172:5598-5605.
34. De Filette M., Fiers W., Martens W., Birkett A., Ramne A., Löwenadler B., et al. Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine 2006, 24:6597-6601.
35. Schotsaert M., Ysenbaert T., Neyt K., Ibañez L.I., Bogaert P., Schepens B., et al. Natural and long-lasting cellular immune responses against influenza in the M2e-immune host. Mucosal Immunol 2013, 6:276-287.